Seno Medical Instruments, Inc. news
Seno Medical Instruments, Inc. (Seno Medical), a Texas-based medical imaging company developing breakthrough breast cancer diagnostic technology, announced an educational partnership supporting Worldwide Breast Cancer’s “Know Your Lemons” campaign starting with the Netherlands, which has one of the highest breast cancer incidence rates in the world.
Through the partnership with Know Your Lemons, Seno will support educational activities focused on healthcare providers
Seno Medical’s Imagio Breast Imaging System has been named a finalist in the 2022 Edison Awards competition in the Science and Medical category and Diagnostics sub-category.
The Edison Awards program is an annual competition honoring excellence in new product and service development, marketing, human-centered design, and innovation. Past winners
A study presented at the Radiological Society of North America (RSNA)’s annual meeting showed Texas-based Seno Medical Instruments, Inc. (Seno)’s Imagio opto-acoustic ultrasound (OA/US) breast imaging provides significantly better specificity than ultrasound alone. The poster, “Performance of Optoacoustic Ultrasound with an Artificial Intelligence-based Decision Support Tool vs Ultrasound Alone to Classify Benign Versus Malignant Breast Masses:
Texas-based Seno Medical Instruments, Inc. (Seno) has launched its CONFIDENCE registry to evaluate the efficacy of imaging with opto-acoustic/ultrasound (OA/US) to diagnose breast abnormalities including cancer using its groundbreaking Imagio® Breast Imaging System.
Approximately twelve sites will participate in the international registry, with a target of over 600 total patients participating through the study’s timeframe, ending in 2024.
<The Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA) has granted Texas-based Seno Medical Instruments, Inc. (Seno) premarket approval (PMA) for its groundbreaking diagnostic breast cancer imaging technology that helps physicians better differentiate between benign and malignant breast lesions. The company’s Imagio® Breast Imaging System uses non-invasive opto-acoustic ultrasound (OA/US) t